Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner)
Department/location: Cancer Research UK Cambridge Institute (CRUK CI) and the AstraZeneca Discovery Centre
Deadline for application: 17th October 2025
Course start date: 1st October 2026
Project details
Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy Transfer (LET) alpha-particles to cancer cells, maximising efficacy while minimising toxicity. Knowledge about radiation sensitivity, accrued mainly with sparsely ionising low-LET radiation (e.g. X-ray, -ray), demonstrated that genetic backgrounds influence radiation therapy (RT) responses, with DNA-damage response (DDR) pathways critically involved. However, determinants of sensitivity to high-LET radiation, such as alpha particles emitted by TAT, remain largely unexplored.
Emerging data suggest that some cancer cells within the alpha particle emission path only receive sub-lethal levels of DNA damage and can survive. Combining TAT and DDR inhibitors thus has the potential to convert this sub-lethal DNA damage into cancer cell killing.
This project will explore the effects of radioligand therapies on cell viability and DDR activation in established human cell models. The student will perform CRISPR screens to determine factors that affect resistance/sensitivity and follow these up with mechanistic studies of a shortlist of identified targets. These studies may uncover mechanisms of cellular responses, potential biomarkers and additional therapeutic vulnerabilities that underlie the responses of normal and tumour cells to alpha radiotherapy.
References * Awwad, S.W., Serrano-Benitez, A., Thomas, J.C., Gupta, V., and Jackson, S.P. Nurturing a revolution in DNA repair and cancer therapy through CRISPR screens. Nature Reviews Molecular and Cell Biology 2023. 24, 477-494.
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.